One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Varex Imaging Corporation logo
Varex Imaging Corporation VREX
$ 18.41 0.44%
report update icon

Quarterly report 2026-Q3
added 08-10-2026

Varex Imaging Corporation Income Statement 2025-2011 | VREX

Brief overview of income trends at Varex Imaging Corporation

The conclusions below are based on five years of reported results. Varex Imaging Corporation reported revenue of 738 million dollars in 2020 and 845 million dollars by 2025. The cumulative result was +14.4%, corresponding to roughly 2.7% per year. The scale of the core business was largely unchanged.

The gross result shifted from $190 million to $290 million, or +52.7%. Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. Gross margin moved from 25.8% to 34.4%. The business retained more gross profit from each unit of revenue.

EBITDA changed from −$11.4 million to −$4.6 million (+59.6%). The operating result outpaced sales and points to improving efficiency. Comparing the endpoints gives EBITDA margins of −1.5% and −0.5%. Operating profitability remained broadly stable.

Comparing the endpoints shows a move from −57.9 million dollars to −70.3 million dollars. Larger losses indicate rising pressure on the business.

Market value was $621 million at the start and $502 million at the end. The decline in value indicates softer investor confidence.

What the figures show

The results contain several connected negative signals. The constructive conclusion rests on consistent operating efficiency and improving gross profitability. Caution is warranted because of lower net income, a softer top-line trend and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement Varex Imaging Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

502 M 577 M 752 M 889 M 1.24 B 621 M 1.12 B 947 M 1.28 B - - - - - -

Shares

41.4 M 40.8 M 40.3 M 39.8 M 39.3 M 38.8 M 38.6 M 38.4 M 38 M - - - - - -

Historical Prices

12.1 14.1 18.6 22.3 31.6 16.7 29.8 23.7 40.2 - - - - - -

Net Income

-70.3 M -48.8 M 47.4 M 30.3 M 17.4 M -57.9 M 15.5 M 27.5 M 51.6 M 68.5 M 80 M 110 M 110 M - -

Revenue

845 M 811 M 893 M 859 M 818 M 738 M 781 M 773 M 698 M 620 M 632 M 685 M 670 M - -

Cost of Revenue

554 M 554 M 603 M 576 M 547 M 548 M 524 M 520 M 445 M 372 M 382 M - - - -

Gross Profit

290 M 257 M 290 M 284 M 272 M 190 M 257 M 254 M 254 M 248 M 251 M 279 M 268 M - -

Operating Income

-27.8 M 32.1 M 77.1 M 88.2 M 74.1 M -33.7 M 45.7 M 44.5 M 83.7 M 109 M 128 M - - - -

Interest Expense

-4.4 M -4.2 M 29.3 M 39.8 M 42.1 M 31.4 M 21.1 M 21.7 M 12.3 M 1.9 M 1.2 M - - - -

EBITDA

-4.6 M 53.3 M 96.6 M 107 M 94.6 M -11.4 M 84.9 M 86.7 M 111 M 124 M 140 M 186 M 179 M - -

Operating Expenses

318 M 225 M 213 M 195 M 197 M 224 M 211 M 209 M 170 M 139 M 123 M 103 M 99.3 M - -

General and Administrative Expenses

133 M 138 M 128 M 118 M 126 M 142 M 128 M 126 M 102 M 85.8 M - - - - -

All numbers in USD currency

Quarterly Income Statement Varex Imaging Corporation

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

41.5 M 42 M 41.8 M 41.8 M 41.7 M 41.5 M 41.4 M 41.1 M 41.1 M 40.9 M 40.7 M 40.6 M 40.5 M 40.4 M 40.2 M 40.1 M 40.1 M 39.9 M 39.7 M 39.5 M 39.4 M 39.4 M 39.2 M 38.5 M 38.7 M 39 M 38.6 M - 38.2 M 38.3 M 38.2 M 38.1 M 37.8 M 37.9 M 38.1 M 37.7 M 37.5 M 37.6 M 37.7 M 37.4 M 37.4 M 37.4 M 37.4 M - - - - - - - - - - - - - - - - - - - -

Net Income

-89.1 M -8.1 M 2.3 M 2.3 M - -89.1 M 6.9 M -300 K - 1.4 M 1.4 M -500 K - 9.1 M 4.1 M 3.1 M - 8.2 M 7.6 M 1.4 M - 12 M 3.1 M -1.3 M -31.5 M -28.3 M -1.9 M - 7.4 M -1.4 M 5.8 M 3 M 27.5 M 3.8 M 3 M 11.3 M 36.8 M 10.6 M 11.3 M 11.1 M 46.5 M 17.6 M 11.1 M - - - - - - - - - - - - - - - - - - - -

Revenue

203 M 216 M 210 M 210 M - 203 M 213 M 200 M - 209 M 206 M 190 M - 232 M 228 M 206 M - 214 M 215 M 199 M - 211 M 204 M 200 M 568 M 171 M 197 M - 578 M 197 M 196 M 186 M 569 M 191 M 201 M 176 M 482 M 170 M 155 M 157 M 448 M 151 M 157 M - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

136 M 143 M 140 M 140 M - 136 M 136 M 131 M - 142 M 140 M 133 M - 156 M 156 M 142 M - 141 M 144 M 134 M - 137 M 139 M 139 M 423 M 145 M 139 M - 393 M 136 M 131 M 126 M 374 M 128 M 131 M 115 M 307 M 111 M 97.2 M 98.6 M 269 M 88.4 M 98.6 M - - - - - - - - - - - - - - - - - - - -

Gross Profit

67.5 M 72.6 M 69.8 M 69.8 M - 67.5 M 76.7 M 68.5 M - 66.9 M 65.8 M 57.1 M - 76.3 M 72.7 M 63.3 M - 73.4 M 70.8 M 64.8 M - 74.1 M 64.6 M 61.1 M 145 M 26.3 M 57.6 M - 185 M 60.7 M 64.4 M 60 M 195 M 63 M 60 M 61.5 M 176 M 59.5 M 61.5 M 58.8 M 179 M 63 M 58.8 M - - - - - - - - - - - - - - - - - - - -

Operating Income

-80.7 M 14.4 M 15.4 M 15.4 M - -80.7 M 22.1 M 11.2 M - 9.3 M 7.7 M 4.2 M - 24.2 M 15.6 M 13 M - 23 M 26.6 M 14 M - 25.7 M 15.8 M 4.6 M -20.8 M -26.8 M 1.4 M - 29.5 M 4.6 M 14.5 M 10.4 M 38.1 M 7.3 M 10.4 M 13.6 M 57.1 M 15.5 M 13.6 M 18.6 M 76.1 M 28.4 M 18.6 M - - - - - - - - - - - - - - - - - - - -

Interest Expense

1 M -4 M -4.3 M -4.3 M - 1 M -4 M -2.8 M - -2.9 M 700 K 600 K - -700 K 7.3 M 7.5 M - 9.4 M 11.1 M 9.9 M - 10.6 M 10.4 M 5.4 M 16.9 M 6.9 M 4.6 M - 15.7 M 5.1 M 5.5 M 5.1 M 16.5 M 5.4 M 5.1 M 5.5 M 5.8 M 4.2 M 5.5 M 600 K 1.3 M 400 K 600 K - - - - - - - - - - - - - - - - - - - -

EBITDA

-79.7 M 25.8 M 21.1 M 21.1 M - -79.7 M 23.1 M 17.4 M - 11 M 11.3 M 9.3 M - 27.6 M 19 M 17.6 M - 26.7 M 30.3 M 18.8 M - 36.2 M 20.1 M 9.8 M -3.5 M -15.4 M 5.8 M - 48.2 M 18.7 M 18.1 M 20.2 M 54.1 M 17.8 M 20.2 M 18.5 M 67.7 M 24 M 18.5 M 21.7 M 83.3 M 32.8 M 21.7 M - - - - - - - - - - - - - - - - - - - -

Operating Expenses

148 M 58.2 M 54.4 M 54.4 M - 148 M 54.6 M 57.3 M - 57.6 M 58.1 M 52.9 M - 52.1 M 57.1 M 50.3 M - 50.4 M 44.2 M 50.8 M - 48.4 M 48.8 M 56.5 M 166 M 53.1 M 56.2 M - 156 M 56.1 M 49.9 M 49.6 M 157 M 55.7 M 49.6 M 47.9 M 119 M 44 M 47.9 M 40.2 M 103 M 34.6 M 40.2 M - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

32.9 M 36 M 32.7 M 32.7 M - 32.9 M 32.6 M 33.8 M - 35.6 M 35.5 M 32.4 M - 32.1 M 34.1 M 30.3 M - 30.2 M 25.3 M 33.1 M - 29.2 M 30.6 M 34.8 M 102 M 31.4 M 35.3 M - 92.3 M 31.2 M 30.3 M 30.8 M 94.3 M 35.2 M 30.8 M 28.2 M 73.3 M 26.3 M 28.2 M 26.9 M 63.5 M 20.6 M 26.9 M - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Varex Imaging Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Orthofix Medical Orthofix Medical
OFIX
$ 9.38 0.21 % $ 371 M curacaoCuracao
TransMedics Group TransMedics Group
TMDX
$ 70.78 1.32 % $ 2.41 B usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 10.46 1.37 % $ 1.57 B usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 54.8 1.69 % $ 8.32 B usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 104.89 0.19 % $ 183 B usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 4.11 34.31 % $ 256 M usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Electromed Electromed
ELMD
$ 27.42 0.07 % $ 227 M usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 59.18 0.15 % $ 1.75 B costa-ricaCosta-rica
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 5.15 0.57 % $ 3.47 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 77.58 0.01 % $ 4.23 B britainBritain
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
LENSAR LENSAR
LNSR
$ 5.8 1.0 % $ 69.4 M usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.78 3.93 % $ 72.4 M usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.16 3.22 % $ 19.6 M usaUSA
Zynex Zynex
ZYXI
- - $ 21.1 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Align Technology Align Technology
ALGN
$ 147.31 0.83 % $ 10.7 B usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.55 0.39 % $ 105 M usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 44.39 0.53 % $ 65.7 B usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 353.7 0.71 % $ 9.64 B usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 9.07 4.33 % $ 257 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
InspireMD InspireMD
NSPR
$ 0.46 0.29 % $ 29.6 M israelIsrael
Butterfly Network Butterfly Network
BFLY
$ 7.25 3.43 % $ 1.79 B usaUSA